ArticleVirchows Archiv : an international journal of pathology2026
FGFR2 amplification and fusion identified by NGS align with FGFR2b overexpression.
Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
FGFR2b is an emerging therapeutic target in HER2-negative advanced gastric cancer (AGC). However, diagnostic concordance between FGFR2b immunohistochemistry (IHC) and genomic assays has been inconsistent due to tumor heterogeneity. The clinical relevance of FGFR2 fusion also remains unclear given its low prevalence. This study assessed the diagnostic concordance and clinical significance of FGFR2b overexpression and FGFR2 genomic alterations using whole-slide surgical specimens. A total of 113 AGC gastrectomy specimens underwent FGFR2b IHC (FPR2-D antibody) and tissue-based next-generation sequencing (NGS) with the TruSight Oncology 500 assay. FGFR2b positivity followed FORTITUDE criteria (≥ 10% moderate-to-strong membranous staining). FGFR2b IHC positivity was 10.6%, and FGFR2 amplification was detected in 13.3% of cases. Surgical specimens demonstrated substantial concordance between IHC and NGS (κ = 0.62), which further improved when FGFR2 fusion was incorporated (κ = 0.67). FGFR2 fusion was relatively rare (5.3%) but associated with both amplification and FGFR2b overexpression (83% and 67%, respectively). Fusion-positive patients showed significantly worse overall survival (p = 0.02). In conclusion, adequate surgical tissue enables strong concordance between FGFR2b IHC and NGS. FGFR2b IHC is an effective frontline screen, while NGS is essential for detecting rare FGFR2 fusions that define an aggressive, poor‑prognosis subtype.
Indexed as
Identifiers
42484843What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.